DSP-2230

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
DSP-2230
DSP-2230.svg
Clinical data
Routes of
administration
By mouth
Identifiers
CAS Number
ChEMBL
Chemical and physical data
FormulaC20H20F3N5O2
Molar mass419.408 g·mol−1
3D model (JSmol)

DSP-2230 is a selective small-molecule Nav1.7 and Nav1.8 voltage-gated sodium channel blocker which is under development by Dainippon Sumitomo Pharma for the treatment of neuropathic pain.[1][2] As of June 2014, it is in phase I/phase II clinical trials.[1][2]

See also[edit]

References[edit]

  1. ^ a b Martz L (2014). "Nav-i-gating antibodies for pain". Science-Business EXchange. 7 (23): 662. doi:10.1038/scibx.2014.662. ISSN 1945-3477.
  2. ^ a b Bagal SK, Chapman ML, Marron BE, Prime R, Storer RI, Swain NA (August 2014). "Recent progress in sodium channel modulators for pain". Bioorganic & Medicinal Chemistry Letters. 24 (16): 3690–9. doi:10.1016/j.bmcl.2014.06.038. PMID 25060923.

External links[edit]

  • "DSP-2230". AdisInsight. Springer Nature Switzerland AG.